Composition for detecting RHO gene polymorphism

The detection of 6 missense mutation sites of the RHO gene in a single tube reaction through multiplex PCR and nucleic acid mass spectrometry technology has solved the problem of difficulty in early diagnosis of retinal pigmentation, achieved rapid and accurate mutation detection, and supported early intervention.

CN119082295APending Publication Date: 2024-12-06SANSURE BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411396496.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to detect missense mutations in the RHO gene quickly and accurately, resulting in difficulty in early diagnosis of retinal pigmentation and affecting timely intervention.

Method used

Using multiplex PCR technology and nucleic acid mass spectrometry, the six missense mutation sites of the RHO gene were detected simultaneously in a single tube reaction through time-of-flight mass spectrometry (MALD1-TOF-MS) technology, combining upstream and downstream primers and single-base extension primers to achieve High throughput detection.

Benefits of technology

It has achieved rapid and accurate detection of RHO gene mutations, low sample size and high sensitivity, and can promptly assist early intervention in retinal pigment degeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082295A_ABST
    Figure CN119082295A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of molecular biological detection, and particularly relates to a composition and a method for joint detection and distinguishing of six missense mutation sites (c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A) of an RHO gene, and application of the composition and the method for joint detection and distinguishing of the six missense mutation sites (c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A) of the RHO gene. The multiplex PCR technology and the nucleic acid mass spectrum are adopted, and the six missense mutation sites c.50C > T, c.68C > A, c.151G > C, c.310G > A, c.403C > T and c.647T > A of the RHO gene can be simultaneously detected in one tube of reaction liquid. Nucleic acid extraction and single-tube PCR amplification only need to be carried out once for one sample, the needed sample size is low, sensitivity and accuracy are high, the detection limit is low, and early intervention of retinitis pigmentosa can be timely and effectively assisted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of molecular biological detection, and in particular, relates to a composition, method and use for joint detection and differentiation of six missense mutation sites (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A) of the RHO gene. Background Art

[0002] Retinitis pigmentosa (RP) is an inherited retinal neurodegenerative disease characterized by progressive photoreceptor cell death and retinal pigment epithelial (RPE) cell atrophy. It initially manifests as night blindness, tubular vision, and retinal pigment deposition. Generally, rod cells are affected first, followed by cone cell degeneration, which can eventually lead to blindness.

[0003] RP is the main cause of hereditary blindness in humans. The global prevalence of RP is 1 / 7000-1 / 3000, and about 1 / 4000 in China. The etiology of the disease is complex. RP has a high degree of genetic heterogeneity. More than 90 pathogenic genes have been found in genetics. RP has a complex inheritance pattern, mainly including autosomal dominant retinitis pigmentosa (adRP, accounting for 30-40% of RP), autosomal recessive retinitis pigmentosa (arRP, accounting for 50-60% of RP), X-linked recessive inheritance (X-linked retinitis pigmentosa, XLRP, accounting for 5-15% of RP), and low incidence of double gene inheritance and mitochondrial inheritance.

[0004] The main pathogenic genes of autosomal dominant adRP are RHO, PRPF31, RP1, etc., among which RHO has the highest morbidity, accounting for 26% of adRP. RHO gene mutation is considered to be the pathogenic gene of RP inherited in an autosomal dominant manner; studies have shown that RHO encodes rhodopsin; rhodopsin is the visual pigment of rod cells, which regulates the membrane potential of cells by changing the concentration of cyclic guanosine monophosphate, generates electrical signals, and transmits them to the visual cortex through the optic nerve to form vision. Most RHO mutations lead to high levels of rhodopsin expression in photoreceptor cells, causing a large number of mutant proteins to be abnormally located and aggregated in cells, causing photoreceptor cell apoptosis, unable to perform normal light signal transmission function, hindering the transmission of light signals, and ultimately leading to blindness. These studies have shown that RHO plays an important role in maintaining the signal transduction process of photoreceptor cells in the eye. Missense mutations in the RHO gene lead to apoptosis of photoreceptor cells, affecting their normal phototransduction function, and ultimately leading to blindness.

[0005] Therefore, there is a need in the art for a product and method that can quickly and accurately detect missense mutations of the RHO gene at an early stage, so as to facilitate early intervention of retinitis pigmentosa. Summary of the invention

[0006] In view of this, six missense mutation sites of the RHO gene were selected (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A), and a high-throughput detection of these six mutation sites using a single reaction based on time-of-flight mass spectrometry (MALD1-TOF-MS) technology was established.

[0007] In a first aspect, the present invention provides a composition for detecting RHO gene polymorphic sites, comprising:

[0008] First nucleic acid composition:

[0009] Upstream and downstream primers for detecting c.50C>T as shown in SEQ ID NOs: 1-2;

[0010] Upstream and downstream primers for detecting c.68C>A as shown in SEQ ID NOs: 1-2;

[0011] Upstream and downstream primers for detecting c.151G>C as shown in SEQ ID NOs: 5-6;

[0012] Upstream and downstream primers for detecting c.310G>A as shown in SEQ ID NOs: 8-9;

[0013] Upstream and downstream primers for detecting c.403C>T as shown in SEQ ID NOs: 11-12; and

[0014] Upstream and downstream primers for detecting c.647T>A as shown in SEQ ID NOs: 14-15; and

[0015] Second nucleic acid composition:

[0016] A single base extension primer for detecting c.50C>T as shown in SEQ ID NO:3;

[0017] A single base extension primer for detecting c.68C>A as shown in SEQ ID NO:4;

[0018] a single base extension primer for detecting c.151G>C as shown in SEQ ID NO:7;

[0019] a single base extension primer for detecting c.310G>A as shown in SEQ ID NO:10;

[0020] A single base extension primer for detecting c.403C>T as shown in SEQ ID NO:13; and

[0021] A single base extension primer for detecting c.647T>A is shown in SEQ ID NO:16.

[0022] Furthermore, the first nucleic acid composition is subjected to a multiplex PCR reaction, and the second nucleic acid composition is subjected to a single base extension reaction.

[0023] In the present invention, the Genebank accession number of the RHO gene is NM_000539.3.

[0024] The present invention adopts multiplex PCR technology and nucleic acid mass spectrometry. Six missense mutation sites of the RHO gene c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A can be detected simultaneously in one tube of reaction solution. For one sample, only one nucleic acid extraction and single-tube PCR amplification are required, the required sample amount is low, the sensitivity and accuracy are high, the detection limit is low, and the RHO gene mutation can be detected in a timely and effective manner to assist in the early intervention of retinitis pigmentosa.

[0025] Furthermore, the composition includes upstream and downstream primers for detecting the internal standard and a single base extension primer.

[0026] In some specific embodiments, the internal standard is a human internal standard gene. In a specific embodiment, the internal standard is a human housekeeping gene.

[0027] Further, in some embodiments, the composition of the present invention may include one or more sets of the above primer pairs and single-base extension primers. In the present invention, "set" refers to mutually matching upstream and downstream primers and single-base extension primers for detecting a target.

[0028] The composition of the present invention can be combined into any combination of the corresponding six targets. Those skilled in the art can combine as needed to detect which targets, that is, to combine the primer pairs corresponding to the targets and the single-base extension primers. These combinations are all included in the present invention.

[0029] For example, any 5 of the 6 sets of primers, any 4 of the 6 sets of primers, any 3 of the 6 sets of primers, any 2 of the 6 sets of primers, and any 1 of the 6 sets of primers.

[0030] In a specific embodiment, the components of the first nucleic acid composition of the present invention are present in one package; and the components of the second nucleic acid composition are present in another package.

[0031] Furthermore, the components of the package of the present invention are present in a mixed form.

[0032] In a second aspect, the present invention provides the use of the above-mentioned composition for detecting RHO gene polymorphic sites in the preparation of a kit for detecting retinitis pigmentosa, wherein the 6 missense mutation sites are c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, and c.647T>A.

[0033] In a third aspect, the present invention provides a kit for detecting RHO gene polymorphic sites, wherein the kit comprises the composition of the present invention as described above.

[0034] Furthermore, the kit also includes DNA polymerase, dNTP, PCR buffer and Mg 2+ At least one of .

[0035] Furthermore, the kit further comprises at least one of SAP enzyme and SAP buffer.

[0036] Furthermore, the kit further comprises at least one of a single-base extension reaction enzyme, a single-base extension buffer, and a single-base extension termination solution.

[0037] Furthermore, the concentration of the DNA polymerase is 3U / reaction to 15U / reaction, for example, the DNA polymerase may be Taq enzyme.

[0038] Furthermore, the kit also includes a negative quality control product and a positive quality control product.

[0039] In a specific embodiment, the negative control is at least one of DEPC H2O, physiological saline, and an internal standard gene. The positive control is a wild-type and mutant clone plasmid of the RHO gene.

[0040] Furthermore, the kit also includes a nucleic acid releasing reagent and a nucleic acid extracting reagent.

[0041] In a specific embodiment, the kit of the present invention comprises: Taq enzyme, SAP enzyme, single base extension enzyme, Mg 2+ , dNTPs, primers, PCR buffer, SAP buffer, single base extension buffer, single base extension termination solution, the primers include upstream and downstream primers and single base extension primers.

[0042] In a specific embodiment, the total volume of the reaction in a single PCR reaction tube is 8-18 μL.

[0043] In a fourth aspect, the present invention provides a use of a composition for preparing a reagent for detecting RHO gene polymorphic sites, wherein the detection comprises the following steps:

[0044] 1) Extracting or releasing nucleic acid from the sample to be tested;

[0045] 2) performing PCR amplification on the nucleic acid obtained in step 1) using the composition of the present invention or the kit of the present invention as described above;

[0046] 3) performing a SAP reaction on the product obtained in step 2);

[0047] 4) performing a single base extension reaction on the product obtained in step 3);

[0048] 5) Obtain and analyze the results.

[0049] In the present invention, the sample used for detection may be serum, blood, etc., but is not limited thereto.

[0050] Furthermore, the reaction conditions of the PCR are:

[0051] Pre-denaturation, temperature is 95℃, time is 120 seconds, 1 cycle; denaturation, temperature is 95℃, time is 30 seconds, annealing, temperature is 56℃, time is 30 seconds, extension, temperature is 72℃, time is 1 minute, 45 cycles, and finally continue extension at 72℃ for 5 minutes, 1 cycle.

[0052] Furthermore, the SAP reaction conditions are: 37° C. for 40 minutes and 85° C. for 5 minutes.

[0053] Furthermore, the single base extension reaction conditions are: 95°C for 30s, (95°C for 5s, (52°C for 5s, 80°C for 5s) for 5 cycles) for 40 cycles, and 72°C for 3 minutes.

[0054] In a fifth aspect, the present invention provides a method for detecting RHO gene polymorphic sites for non-diagnostic purposes, the method comprising the following steps:

[0055] 1) Extracting or releasing nucleic acid from the sample to be tested;

[0056] 2) performing PCR amplification on the nucleic acid obtained in step 1) using the composition of the present invention or the kit of the present invention;

[0057] 3) performing a SAP reaction on the product obtained in step 2);

[0058] 4) performing a single base extension reaction on the product obtained in step 3);

[0059] 5) Obtain and analyze the results.

[0060] Furthermore, the reaction conditions of the PCR are:

[0061] Pre-denaturation, temperature is 95℃, time is 120 seconds, 1 cycle; denaturation, temperature is 95℃, time is 30 seconds, annealing, temperature is 56℃, time is 30 seconds, extension, temperature is 72℃, time is 1 minute, 45 cycles, and finally continue extension at 72℃ for 5 minutes, one cycle.

[0062] Furthermore, the SAP reaction conditions are: 37° C. for 40 minutes and 85° C. for 5 minutes.

[0063] Furthermore, the single base extension reaction conditions are: 95°C for 30s, (95°C for 5s, (52°C for 5s, 80°C for 5s) for 5 cycles) for 40 cycles, and 72°C for 3 minutes. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 This is a graph showing the detection results of the composition of the present invention detecting RHO gene polymorphic sites;

[0065] Figures 2 to 7 The detection result diagram of the composition of the present invention detecting the RHO gene polymorphism site is a screenshot of each site (RHO: c.50C>T, RHO: c.68C>A, RHO: c.151G>C, RHO: c.310G>A, RHO: c.403C>T and RHO: c.647T>A respectively);

[0066] Figure 8 This is a sensitivity test result diagram of the composition of the present invention;

[0067] Fig. 9 This is a graph showing the results of the anti-interference test of the composition of the present invention;

[0068] Fig.10This is a graph showing the detection results of the comparative example composition of the present invention for detecting RHO gene polymorphic sites; DETAILED DESCRIPTION

[0069] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.

[0070] Example 1: Primers used in the present invention

[0071] The upstream and downstream primers and single base extension primers used in the present invention are shown in Table 1, wherein the 5' end of the upstream and downstream primers (SEQ ID NO: 1, 2, 5, 6, 8, 9, 11, 12, 14, 15) is provided with an auxiliary sequence ACGTTGGATG.

[0072] Table 1

[0073]

[0074] Example 2: Method for detecting retinitis pigmentosa

[0075] Reagent preparation:

[0076] Nucleic acid extraction or purification reagent (S4005) produced by Shengxiang Biotechnology Co., Ltd. is used to extract nucleic acid from whole blood samples. The extracted DNA is tested within a short period of time (within 6 hours) or frozen at -20℃±5℃ for a long time, and the storage time does not exceed 1 year.

[0077] PCR reaction reagents, SAP reaction reagents and single-base extension reaction reagents: Nucleic acid purification reagents (Zhehangxiebei No. 20220893) were purchased from Hangzhou Juzhi Biotechnology Co., Ltd. The nucleic acid purification reagents include PCR buffer, PCR enzyme, SAP buffer, SAP enzyme, extension buffer, extension stop solution, and extension enzyme.

[0078] Take out the PCR multiple primer reaction solution, PCR buffer, PCR enzyme, etc. from the kit, melt and shake at room temperature, centrifuge at 2000rpm for 10s, and mix thoroughly. Mix each component thoroughly in the liquid preparation chamber according to the amount shown in Table 2, dispense 4μL into the PCR reaction tube, and transfer to the sample processing area.

[0079] Table 2

[0080]

[0081] Loading sample on machine

[0082] Add 1 μL (concentration 30 ng / μL) of whole blood DNA extraction sample, cover the reaction tube tightly, shake briefly, centrifuge (4000 rpm, 5 seconds), and then quickly load the obtained PCR reaction tube reagent onto the machine.

[0083] PCR amplification

[0084] Place the PCR reaction tube into the sample slot of the amplification instrument and perform amplification according to Table 3 below.

[0085] Table 3

[0086]

[0087]

[0088] SAP response

[0089] The SAP reaction solution was prepared according to Table 4. 2 ul of the SAP reaction solution was added to each 0.2 mL PCR reaction tube and the SAP reaction was performed at 37°C for 40 min, 85°C for 5 min, and 4°C∞ (i.e., kept at 4°C).

[0090] Table 4

[0091]

[0092] Single base extension reaction

[0093] The single base extension reaction solution was prepared according to Table 5, 2 ul of the single base extension reaction solution was added to each 0.2 mL PCR reaction tube, and the single base extension reaction was performed according to 95°C 30 s, (95°C 5 s, (52°C 5 s, 80°C 5 s)*5)*40, 72°C 3 min, 4°C∞ (i.e., always maintained at 4°C).

[0094] Table 5

[0095]

[0096] Interpretation of Test Results

[0097] All the above reaction products were transferred to a 96 / 384-well PCR plate. After adding 18 μL of ultrapure water to each sample, the mixture was briefly shaken and then centrifuged (4000 rpm, 5 seconds). Finally, the PCR plate was transferred to a time-of-flight mass spectrometry detection system for the experiment.

[0098] According to the molecular weight of the single-base extension primer and the primer extension, the genotype at the target site is judged. The judgment principle is: SNR (signal-to-noise ratio) ≥ 3, peak ≥ 2, the weight interval of each target fragment is at least 16 Daltons, and the signal is not oversaturated, the signal between each target is relatively flat, and there is no broad peak or double peak phenomenon. According to the following Table 6, the mutation site is judged. If the wild-type molecular weight position peaks, it is wild-type; if the mutant molecular weight position peaks, it is a homozygous mutation; if both positions have peaks, it is a heterozygous mutation.

[0099] Table 6

[0100] Mutation site wild type Molecular weight Homozygous mutation Molecular weight Heterozygous mutation c.50C>T C 5024.4 T 5104.4 CT c.68C>A C 5514.6 A 5538.6 CA c.151G>C G 4573 C 4533 GC c.310G>A G 6017 A 6001 GA c.403C>T C 6469.2 T 6549.2 CT c.647T>A T 7512 A 7456 TA

[0101] Example 3: Test results of the test samples of the composition of the present invention

[0102] The method of the present invention includes two cycle steps, which are a multiple amplification step and a single base extension step. After the multiple amplification step amplifies the six missense mutation sites, the single base extension step extends one base backward on the amplified fragment through the designed primer. In the present invention, the results of the relevant sites are detected using a Shengxiang nucleic acid mass spectrometer. When a peak graph is displayed on the corresponding base, it means that the corresponding missense mutation site has been detected.

[0103] The primers shown in Example 1 were used to detect and distinguish the mixed samples of 6 missense mutation sites according to the method of Example 2. The detection results are as follows: Figures 1 to 7 As shown ( Figures 2 to 7 yes Figure 1 ), it can be seen from the figure that the primer combination for detecting the polymorphic site of the RHO gene for retinitis pigmentosa in Example 1 combined with time-of-flight mass spectrometry can detect all mutation sites (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A), with high peak and specificity, and SNR value greater than 3. In 24 parallel experiments, all RHO gene polymorphic sites (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A) were detected with an accuracy of 100%, and the results are shown in Table 7.

[0104] Table 7

[0105] SNP ID Accuracy RHO:c.50C>T 100%(24 / 24) RHO:c.68C>A 100%(24 / 24) RHO:c.151G>C 100%(24 / 24) RHO:c.310G>A 100%(24 / 24) RHO:c.403C>T 100%(24 / 24) RHO:c..647T>A 100%(24 / 24)

[0106] If mutations in the above six gene loci (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A) are found in patients diagnosed with retinitis pigmentosa, the presence of mutations in a single gene locus can confirm that the patient is a patient with retinitis pigmentosa.

[0107] Example 4: Sensitivity of the composition of the present invention

[0108] The primer combination for detecting RHO gene polymorphic sites provided in Example 1 was used to perform sensitivity detection on RHO gene polymorphic sites (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A). The concentration of the whole blood DNA sample for retinitis pigmentosa was 5 ng / μL. The detection results were as follows: Figure 8 As shown, Figure 8 A is: c.50C>T; B is: c.68C>A; C is: c.151G>C; D is: c.310G>A; E is: c.403C>T; F is: c.647T>A. The test results are shown in Table 8 and Figure 8 As shown in Table 8, when the concentration of the whole blood DNA sample of retinitis pigmentosa is 5 ng / μL, the detection is repeated 10 times in parallel, and the primer combination for detecting the RHO gene polymorphic site provided in Example 1 has a detection rate of 100% for the RHO gene polymorphic site (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A). Figure 8 It can be seen that the primer combination of the present invention combined with time-of-flight mass spectrometry can detect all mutation sites (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A) of the RHO gene in a whole blood DNA sample of retinitis pigmentosa with a concentration of 5 ng / μL, with a high peak and specificity, and an SNR value greater than 3. This fully demonstrates that the analytical sensitivity of the primer combination of the present invention is 5 ng / μL.

[0109] Table 8

[0110] SNP ID Sensitivity (5ng / μL) RHO:c.50C>T 100%(10 / 10) RHO:c.68C>A 100%(10 / 10) RHO:c.151G>C 100%(10 / 10) RHO:c.310G>A 100%(10 / 10) RHO:c.403C>T 100%(10 / 10) RHO:c.647T>A 100%(10 / 10)

[0111] Example 5: Anti-interference performance of the composition of the present invention

[0112] Nucleic acid extraction or purification reagents were used for nucleic acid extraction, and then a spectrophotometer was used for detection. The sample was diluted to the critical concentration, and endogenous interfering substances, exogenous interfering substances, and drug interference were added respectively. The final concentration of the interfering substances was adjusted as shown in Table 9. The samples without adding interfering substances were used as controls, and the corresponding genotypes were accurately detected, as shown in Table 10.

[0113] Table 9

[0114]

[0115]

[0116] Table 10

[0117]

[0118] Fig. 9 This is the nucleic acid mass spectrometry test result diagram of each point of sample F1 (the inhibitor is EDTA-Na2). Fig. 9 A is: c.50C>T; B is: c.68C>A; C is: c.151G>C; D is: c.310G>A; E is: c.403C>T; F is: c.647T>A. Fig. 9 It can be seen that, in the case of adding interfering substances, the present embodiment can also accurately detect all polymorphic sites of the RHO gene of retinitis pigmentosa (c.50C>T, c.68C>A, c.151G>C, c.310G>A, c.403C>T, c.647T>A), with high peak values ​​and specificity, and an SNR value greater than 3, indicating that these interfering substances will not affect the detection reaction of nucleic acid mass spectrometry. This fully demonstrates that the primer composition of the present invention has high specificity and strong anti-interference.

[0119] Example 6: Precision of the composition of the present invention

[0120] Nucleic acid was extracted from whole blood samples using S4005 nucleic acid extraction or purification reagent produced by Shengxiang Biotechnology Co., Ltd., and then the concentration of DNA samples was detected using a spectrophotometer. The original DNA was then diluted to medium concentration samples (30 ng / μL) and critical concentration samples (15 ng / μL), and the tests were repeated 10 times, and all were accurately detected. The results are shown in Table 11 below.

[0121] Table 11

[0122]

[0123] Comparative Example 1: Other primers designed by the present invention with poor effects

[0124] Due to the principle of complementary base pairing, primers will form dimers, but this probability is very low and can be ruled out at the beginning of the design. However, when multiple targets are detected together, there are many primers, and primers and primers are prone to dimers. To ensure the conservatism of the design (conservatism is crucial to the accuracy of the detection), and to consider the mutual interference between different primers, the primers need to be carefully designed.

[0125] Therefore, the inventors also designed some other primers (sequences as shown in Table 12) to form different detection systems, which were also used for 6 missense mutation sites, among which the 5' end of the upstream and downstream primers (SEQ ID NO: 2, 6, 8, 9, 17, 18, 19, 20, 21, 22) was provided with an auxiliary sequence ACGTTGGATG.

[0126] Fig.10 The mass spectra of each site detected in Comparative Example 1, where A is: c.50C>T; B is: c.68C>A; C is: c.151G>C; D is: c.310G>A; E is: c.403C>T; F is: c.647T>A. Fig.10 It can be seen that the three sites A, B, and D in Comparative Example 1 cannot be identified by time-of-flight mass spectrometry. It can be seen that the primer combination for detecting the polymorphic site of the RHO gene in this Comparative Example 1 cannot be used to detect all the corresponding sites of amplification extension, that is, the specific genotype cannot be accurately determined and identified in combination with the time-of-flight mass spectrometer.

[0127] Table 12

[0128]

Claims

1. A composition for detecting RHO gene polymorphic sites, comprising: First nucleic acid composition: Upstream and downstream primers for detecting c.50C>T as shown in SEQ ID NOs: 1-2; Upstream and downstream primers for detecting c.68C>A as shown in SEQ ID NOs: 1-2; Upstream and downstream primers for detecting c.151G>C as shown in SEQ ID NOs: 5-6; Upstream and downstream primers for detecting c.310G>A as shown in SEQ ID NOs: 8-9; Upstream and downstream primers for detecting c.403C>T as shown in SEQ ID NOs: 11-12; and Upstream and downstream primers for detecting c.647T>A as shown in SEQ ID NOs: 14-15; and Second nucleic acid composition: A single base extension primer for detecting c.50C>T as shown in SEQ ID NO:3; A single base extension primer for detecting c.68C>A as shown in SEQ ID NO:4; a single base extension primer for detecting c.151G>C as shown in SEQ ID NO:7; a single base extension primer for detecting c.310G>A as shown in SEQ ID NO:10; a single base extension primer for detecting c.403C>T as shown in SEQ ID NO:13; as well as A single base extension primer for detecting c.647T>A is shown in SEQ ID NO:

16.

2. The composition according to claim 1, characterized in that The first nucleic acid composition further includes upstream and downstream primers for detecting the internal standard, and the second nucleic acid composition further includes a single base extension primer for detecting the internal standard.

3. The composition according to claim 1 or 2, characterized in that The components of the first nucleic acid composition are present in one package; the components of the second nucleic acid composition are present in another package.

4. The composition according to claim 3, characterized in that The components of the package are present in mixed form.

5. Use of the composition according to any one of claims 1 to 4 in the preparation of a kit for detecting retinitis pigmentosa.

6. A kit for detecting RHO gene polymorphic sites, the kit comprising the composition according to any one of claims 1 to 4.

7. The kit according to claim 6, characterized in that The kit also includes at least one of a nucleic acid releasing reagent and a nucleic acid extracting reagent.

8. The kit according to claim 7, characterized in that The kit also includes a negative quality control product and a positive quality control product.

9. The kit according to any one of claims 6 to 8, characterized in that The kit also includes dNTP, DNA polymerase, SAP enzyme, single base extension reaction enzyme, PCR buffer, SAP buffer, single base extension buffer, single base extension stop solution, and Mg 2+ At least one of .

10. Use of a composition for preparing a reagent for detecting RHO gene polymorphic sites, the detection comprising the following steps: 1) Extracting or releasing nucleic acid from the sample to be tested; 2) performing multiplex PCR on the nucleic acid obtained in step 1) using the composition according to any one of claims 1 to 4 or the kit according to any one of claims 6 to 9; 3) performing a SAP reaction on the product obtained in step 2); 4) performing a single base extension reaction on the product obtained in step 3); 5) Obtain and analyze the results.